Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 4, 2013. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 840,000 Ordinary Shares of 25 pence each.
- Purchase Date: June 4, 2013.
- Price Range: Highest price paid was 1,707.0 pence per share; lowest price paid was 1,693.0 pence per share.
- Treasury Holdings (Settled): 503,939,012 shares (9.28% of total issued share capital).
- Treasury Holdings (Including Unsettled): 506,374,512 shares (10.28% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,925,226,443 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 840,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.28% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (503,939,012 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (10.28% held in Treasury including unsettled shares).
- Check the number of shares in issue (4,925,226,443) to ensure accurate denominator usage for Disclosure and Transparency Rule notifications.
- Review the price paid (1,693.0 to 1,707.0 pence) against market trading data for June 4, 2013.